Patient Management

2074 questions

Question 2021Question →

A 66-year-old man presents to the clinic for an annual health maintenance examination. His past medical history is notable for diet-controlled type 2 diabetes mellitus, essential hypertension, and mild osteoarthritis of the right knee. He is a former smoker, having smoked one pack of cigarettes daily for 25 years before quitting exactly 17 years ago. His current medications include lisinopril and acetaminophen as needed.

Review of his preventive health record reveals:
- A screening colonoscopy at age 62 was unremarkable.
- An abdominal aortic aneurysm screening ultrasound at age 65 showed a normal aorta.
- He completed a primary hepatitis B vaccination series at age 55.
- He received the two-dose recombinant zoster vaccine series at age 50.
- He received his annual influenza vaccine last month.
- He has never received any pneumococcal vaccines.

Physical examination today is unremarkable. His blood pressure is 126/78 mm Hg, and his body mass index is 26 kg/m². Which of the following is the most appropriate next step in this patient's preventive care?

Show answer & explanation

Answer: Administer the 20-valent pneumococcal conjugate vaccine (PCV20)

Answer

Administer the 20-valent pneumococcal conjugate vaccine (PCV20)
Current Advisory Committee on Immunization Practices (ACIP) guidelines state that all adults aged 65 years and older who have not previously received a pneumococcal conjugate vaccine should receive a single dose of the 20-valent pneumococcal conjugate vaccine (PCV20) alone, or a dose of the 15-valent pneumococcal conjugate vaccine (PCV15) followed by a dose of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) at least one year later. Because this 66-year-old patient is entirely naive to pneumococcal vaccines, initiating the series with PCV20 is the definitive next step in his preventive care.

Step-by-Step Solution

1
Analyze the patient's demographic and social history against screening guidelines.
The patient is 66 years old and quit smoking 17 years ago, meaning he exceeds the 15-year quit window for lung cancer screening.
To rule out the need for low-dose computed tomography (LDCT) and confirm no other age/smoking-based screenings are missed.
2
Review the patient's prior screening and immunization records.
The patient has already received a normal 1-time AAA ultrasound, is up to date on colonoscopy and zoster/influenza/hepatitis B vaccines, but is naive to pneumococcal vaccines.
To prevent ordering duplicate 1-time tests (like AAA screening) and identify outstanding health maintenance gaps.
3
Apply the current ACIP adult immunization schedule for a 66-year-old.
A 66-year-old pneumococcal vaccine-naive adult requires either a single dose of PCV20, or a dose of PCV15 followed by PPSV23 a year later.
Age over 65 is a direct indication for routine pneumococcal vaccination, and conjugate vaccines must initiate the sequence.

Key Concept

Adult Preventive Care and Immunization Guidelines
Question 2022Question →

Targeted antimicrobial therapy is being planned for a 62-year-old female currently receiving mechanical ventilation for severe pneumonia. She was transferred from a skilled nursing facility 3 days ago. Endotracheal aspirate cultures collected on admission have finalized, demonstrating heavy growth of methicillin-resistant Staphylococcus aureus (MRSA). The patient's past medical history is notable for major depressive disorder, generalized anxiety disorder, and osteoarthritis. Her routine home medications, which are currently being administered via an orogastric tube, include citalopram, buspirone, and scheduled acetaminophen. Current laboratory studies show a serum creatinine of 0.8 mg/dL and normal hepatic transaminases. Which of the following intravenous medications is the most appropriate targeted pharmacologic intervention for this patient?

Show answer & explanation

Answer: Intravenous vancomycin

Answer

Intravenous vancomycin is the correct medication because it effectively treats MRSA pneumonia without interacting with the patient's serotonergic medications.
Intravenous vancomycin is the correct choice because it provides reliable, standard-of-care coverage against MRSA pneumonia and lacks the specific contraindications associated with the other active agents in this clinical scenario. Since this patient has normal renal function, vancomycin can be safely administered with appropriate pharmacokinetic trough or AUC monitoring.

Step-by-Step Solution

1
Identify the primary diagnosis and the isolated pathogen.
The patient has severe pneumonia with endotracheal cultures positive for MRSA.
Establishing the specific etiology and infection site is the required first step in selecting targeted antimicrobial therapy.
2
Consider site-specific contraindications for MRSA-active antibiotics.
Daptomycin must be excluded from consideration because it is irreversibly inactivated by pulmonary surfactant and is ineffective for pulmonary infections.
Antimicrobial efficacy depends on achieving therapeutic concentrations of the active drug at the actual site of infection.
3
Evaluate the patient's medication list for potential severe drug-drug interactions.
The patient is taking citalopram and buspirone, which increase serotonergic activity. Linezolid must therefore be avoided due to its MAOI activity and the high risk of serotonin syndrome.
Reviewing concurrent home medications prevents iatrogenic complications from overlapping pharmacodynamics.
4
Select the safest, most effective targeted agent from the remaining options.
Intravenous vancomycin is chosen as it covers MRSA, penetrates pulmonary tissue adequately, and lacks hazardous interactions with the patient's regimen.
Vancomycin represents the standard of care for MRSA pneumonia when linezolid is contraindicated.

Key Concept

Pharmacologic management of MRSA pneumonia requires navigating absolute contraindications, such as daptomycin inactivation by pulmonary surfactant, and severe drug interactions, such as linezolid coadministration with serotonergic agents.
Question 2023Question →

Review the following patient profiles from an outpatient primary care clinic. Match each patient with the most critical, guideline-concordant preventive care intervention required during their visit today.

Click a left item, then click its matching right item

Items

29-year-old gravid patient at 28 weeks gestation; BMI 22 kg/m²; received a tetanus-diphtheria toxoid booster 2 years ago for a minor wound.
71-year-old man; BMI 24 kg/m²; former smoker with a 40 pack-year history who quit 8 years ago; no current pulmonary symptoms.
38-year-old man; BMI 33 kg/m²; never-smoker; blood pressure 118/76 mmHg; reports feeling completely well.
22-year-old woman; BMI 21 kg/m²; sexually active with a new partner; relies on oral contraceptives; completely asymptomatic.

Matches

Show answer & explanation

Answer

The gravid patient matches with Tdap administration. The older former smoker matches with LDCT screening. The middle-aged man with obesity matches with diabetes screening. The young sexually active woman matches with STI screening.
Each match correctly identifies the single most appropriate, guideline-driven intervention for that demographic. The pregnant patient requires Tdap for fetal pertussis immunity. The 71-year-old former smoker remains within the 15-year cessation window for LDCT lung cancer screening. The 38-year-old man requires diabetes screening due to his age and BMI of 33 kg/m². The 22-year-old woman requires routine STI screening based purely on her age and sexual activity status.

Step-by-Step Solution

1
Evaluate the pregnant patient's immunization needs.
Identify that Tdap is required during the 27-36 week window of every pregnancy.
Maternal Tdap vaccination maximizes the passive transfer of pertussis antibodies to the fetus, regardless of prior tetanus boosters.
2
Assess the 71-year-old man's cancer screening eligibility.
Determine he requires a low-dose computed tomography (LDCT) scan.
He meets the criteria of being aged 50-80, having at least a 20 pack-year smoking history, and having quit within the last 15 years.
3
Assess the 38-year-old man's metabolic risk factors.
Identify the need for glycemic screening (HbA1c or fasting glucose).
Current guidelines recommend diabetes screening for asymptomatic adults aged 35-70 who have overweight or obesity (BMI > 25 kg/m²).
4
Evaluate the 22-year-old woman's infectious disease screening needs.
Determine she requires nucleic acid amplification testing for Chlamydia and Gonorrhea.
Annual screening is indicated for all sexually active women aged 24 or younger, even if asymptomatic or using barrier-free contraception.

Key Concept

Applying evidence-based preventive care and screening guidelines across diverse patient demographics and risk factors.
Question 2024Question →

A 64-year-old man is brought to the emergency department by his family due to progressive lethargy, confusion, and worsening constipation over the past week. He has a history of advanced squamous cell carcinoma of the lung. On physical examination, his temperature is 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure is 105/65 mmHg105/65\text{ mmHg}, heart rate is 112/min112\text{/min}, and respiratory rate is 16/min16\text{/min}. The patient is somnolent but arousable to tactile stimuli. The mucous membranes are exceptionally dry, and skin turgor is diminished. There is no jugular venous distention, and lung fields are clear to auscultation.

Laboratory studies show:
Serum calcium: 15.6 mg/dL15.6\text{ mg/dL}
Serum phosphorus: 2.1 mg/dL2.1\text{ mg/dL}
Serum creatinine: 1.2 mg/dL1.2\text{ mg/dL} (baseline 0.9 mg/dL0.9\text{ mg/dL})
Intact parathyroid hormone (PTH): 8 pg/mL8\text{ pg/mL} (Normal: 10−65 pg/mL10-65\text{ pg/mL})

Aggressive intravenous fluid resuscitation with 0.9% sodium chloride is initiated. In addition to continued intravenous fluids, which of the following is the most appropriate pharmacologic intervention?

Show answer & explanation

Answer: Intravenous calcitonin and intravenous zoledronic acid

Answer

Intravenous calcitonin and intravenous zoledronic acid.
The correct intervention pairs a fast-acting agent with a long-acting one. Severe hypercalcemia (defined as serum calcium >14 mg/dL>14\text{ mg/dL}) causes profound volume depletion due to calcium-induced nephrogenic diabetes insipidus. Initial management always involves aggressive isotonic saline hydration to restore intravascular volume and promote renal calcium excretion. However, hydration alone is insufficient. Intravenous calcitonin is administered because it acts rapidly (within 4 to 6 hours) to inhibit osteoclast activity and increase renal calcium excretion. Because tachyphylaxis to calcitonin typically develops within 48 hours, a bisphosphonate (such as intravenous zoledronic acid or pamidronate) is given concurrently. Bisphosphonates provide potent, sustained inhibition of osteoclastic bone resorption, though their onset of action is delayed by 48 to 72 hours.

Step-by-Step Solution

1
Assess the severity and etiology of the hypercalcemia.
The calcium level is greater than 14 mg/dL14\text{ mg/dL} (severe), with a suppressed PTH and low phosphorus in the setting of squamous cell carcinoma, confirming PTH-related peptide (PTHrP) driven hypercalcemia of malignancy.
Severity dictates the urgency of treatment, while the etiology determines the appropriate targeted pharmacotherapy.
2
Evaluate the patient's current volume status and initial intervention.
The patient is profoundly hypovolemic (tachycardia, dry membranes, acute kidney injury) due to calcium-induced nephrogenic diabetes insipidus, justifying the ongoing aggressive normal saline.
Volume status determines whether adjunct therapies like loop diuretics are safe or contraindicated.
3
Select the optimal pharmacologic agents to augment fluid therapy.
Calcitonin is chosen for its rapid onset, while zoledronic acid is given simultaneously to provide sustained inhibition of bone resorption.
Saline alone is insufficient for severe hypercalcemia. A fast-acting and a long-acting agent must be combined to bridge the time gap to efficacy.

Key Concept

The acute pharmacologic management of severe hypercalcemia of malignancy (>14 mg/dL>14\text{ mg/dL}) consists of aggressive isotonic saline, a rapid-acting agent (calcitonin), and a long-acting agent (a bisphosphonate). Loop diuretics are avoided unless clinical volume overload develops.
Estimated Time:1m 30s
Question 2025Question →

An ambulatory patient in her late sixties presents to the clinic to discuss her bone health after recent screening tests. Her dual-energy x-ray absorptiometry (DEXA) demonstrates a lumbar spine T-score of −2.8-2.8 and a femoral neck T-score of −2.4-2.4. She has a history of hypertension but no prior fragility fractures. The physician and patient agree to initiate weekly oral alendronate. Arrange the following interventions in the most appropriate chronological order to safely initiate, monitor, and manage this patient's therapeutic course.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is: Verify baseline calcium/vitamin D, assess early adherence and tolerability, perform a follow-up DEXA scan at 1-2 years, and finally evaluate for a drug holiday at 3-5 years.
The correct sequence mirrors the natural timeline of patient management: safety screening immediately prior to initiation, early clinical monitoring for acute toxicity and adherence, mid-term evaluation of therapeutic efficacy via imaging, and long-term evaluation for cumulative risks necessitating therapy de-escalation.

Step-by-Step Solution

1
Determine the prerequisites for initiation.
Serum calcium and vitamin D levels must be checked.
Bisphosphonates inhibit bone resorption, which can precipitate severe hypocalcemia if the patient lacks adequate calcium and vitamin D stores at baseline.
2
Identify early monitoring requirements.
Clinical follow-up for adherence and gastrointestinal side effects is prioritized next.
Oral nitrogen-containing bisphosphonates carry a high risk of erosive esophagitis and require strict administration protocols (taking with a full glass of water, remaining upright for 30 minutes). Early verification of adherence prevents acute harm.
3
Determine the interval for assessing intermediate drug efficacy.
A repeat DEXA scan is scheduled.
It takes at least 1 to 2 years for significant, measurable changes in bone mineral density to manifest on a DEXA scan. Earlier scanning does not provide clinically actionable data.
4
Determine the protocol for long-term treatment evaluation.
Assessment for a drug holiday is considered.
Because bisphosphonates accumulate in the bone matrix and have a very long half-life, a drug holiday is considered after 3 to 5 years of therapy to reduce the risk of long-term complications like atypical femur fractures.

Key Concept

The chronological protocol for monitoring and evaluating bisphosphonate therapy in patients with osteoporosis.
Question 2026Question →

A 68-year-old man is admitted to the intensive care unit with worsening shortness of breath and progressive lethargy over the past 2 days. He has a history of ischemic cardiomyopathy. Upon arrival, he is obtunded, and his extremities are cold and mottled. Vital signs show a temperature of 36.8∘C36.8^\circ \text{C} (98.2∘F98.2^\circ \text{F}), blood pressure of 72/48 mm Hg72/48 \text{ mm Hg}, heart rate of 118/min118/\text{min}, and respiratory rate of 26/min26/\text{min}. Jugular venous distention is prominent. Lung auscultation reveals bilateral crackles. Cardiac examination shows a summation gallop. A pulmonary artery catheter reveals a cardiac index of 1.5 L/min/m21.5 \text{ L/min/m}^2 (normal: 2.5−4.02.5-4.0) and a pulmonary capillary wedge pressure of 28 mm Hg28 \text{ mm Hg} (normal: 4−124-12).

Arrange the following pharmacologic interventions in the most appropriate chronological sequence for the acute stabilization and subsequent management of this patient's condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: Intravenous norepinephrine, followed by intravenous dobutamine, then intravenous furosemide, and finally oral bisoprolol.
The patient is presenting with 'cold and wet' cardiogenic shock, characterized by profound hypotension, hypoperfusion (lethargy, mottled extremities, low cardiac index), and congestion (crackles, elevated wedge pressure). The most immediate threat to life is the loss of critical perfusion pressure; therefore, restoring mean arterial pressure with a vasopressor (intravenous norepinephrine) is the absolute first step. Once a safe blood pressure foundation is established, an inotrope (intravenous dobutamine) is introduced to treat the primary pump failure and improve the cardiac index. Dobutamine cannot be given first due to its propensity to cause vasodilation and exacerbate severe hypotension. After forward flow and renal perfusion are adequately restored, it is safe to administer loop diuretics (intravenous furosemide) to address the volume overload without risking further ischemic acute kidney injury. Finally, guideline-directed medical therapies such as beta-blockers (oral bisoprolol) are strictly contraindicated in the acute phase due to their negative inotropic effects and are only carefully initiated once the patient is hemodynamically stable, euvolemic, and off vasoactive infusions.

Step-by-Step Solution

1
Identify the patient's primary clinical syndrome and immediate life-threatening derangement.
The patient is in cardiogenic shock ('cold and wet' phenotype) with a severely low cardiac index, elevated filling pressures, and profound hypotension (blood pressure 72/48 mm Hg72/48 \text{ mm Hg}).
Accurate categorization dictates the immediate resuscitation priorities.
2
Select the initial intervention to prevent imminent cardiovascular collapse.
Intravenous norepinephrine is chosen first.
Restoring a minimal mean arterial pressure is the absolute first priority to ensure cerebral and coronary perfusion. Norepinephrine provides robust alpha-1 mediated vasoconstriction.
3
Determine the next step to address the underlying low cardiac output state.
Intravenous dobutamine is added second.
Dobutamine improves myocardial contractility (beta-1 agonist), but its beta-2 mediated vasodilation can precipitate deadly hypotension if given before a vasopressor secures the blood pressure.
4
Address the volume overload (elevated pulmonary capillary wedge pressure).
Intravenous furosemide is administered third.
Aggressive diuresis in a severely hypotensive patient can worsen shock and precipitate acute kidney injury. It should be given only after establishing adequate forward flow and perfusion.
5
Plan for long-term morbidity and mortality reduction.
Oral bisoprolol is scheduled last.
Beta-blockers are strictly contraindicated in acute, uncompensated cardiogenic shock due to their negative inotropic effects. They are initiated only prior to discharge when the patient is stable.

Key Concept

In the management of profound cardiogenic shock ('cold and wet' phenotype with severe hypotension), the sequential priority is to first restore perfusion pressure with vasopressors, second improve cardiac output with inotropes, third relieve congestion with diuretics, and finally initiate long-term beta-blocker therapy only after stabilization.
Question 2027Question →

A physician is reviewing the electronic health record of a male patient born in 1961 ahead of an upcoming wellness visit. The current year is 2026. The patient has a past medical history of mild persistent asthma and hypertension. He currently smokes 1.5 packs of cigarettes daily and has done so for the past 30 years. Medical records indicate that a screening colonoscopy performed 6 years ago revealed no polyps or abnormalities. Hepatitis C screening was negative 3 years ago. His immunization record documents the administration of the 20-valent pneumococcal conjugate vaccine (PCV20) at age 63 and a tetanus, diphtheria, and acellular pertussis (Tdap) booster 4 years ago. He has no history of receiving any formulation of the shingles vaccine. He has never undergone vascular or pulmonary imaging.

Which of the following preventive interventions are currently indicated for this patient? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: One-time screening with ultrasonography of the abdominal aorta; Annual screening with low-dose computed tomography of the chest; Administration of the recombinant zoster vaccine

Answer

The currently indicated interventions are a one-time ultrasound of the abdominal aorta, annual low-dose computed tomography of the chest, and the recombinant zoster vaccine.
The patient is exactly 65 years old and has a 45 pack-year smoking history. This combination makes him eligible for several critical preventive measures. First, the USPSTF recommends a one-time screening for an abdominal aortic aneurysm (AAA) with ultrasonography in men aged 65 to 75 years who have ever smoked. Second, annual lung cancer screening with low-dose computed tomography (LDCT) is recommended for adults aged 50 to 80 years with a 20 pack-year or greater smoking history who currently smoke or quit within the past 15 years. Finally, the two-dose recombinant zoster vaccine series is indicated for all adults aged 50 years and older, regardless of prior herpes zoster infection or vaccination status.

Step-by-Step Solution

1
Calculate the patient's current age based on the provided temporal context.
The patient was born in 1961, and the current year is 2026, making him exactly 65 years old.
Preventive screening guidelines are strictly tied to specific age milestones.
2
Identify the patient's key demographic and lifestyle risk factors.
The patient is a 65-year-old male with a 45 pack-year smoking history (1.5 packs/day × 30 years) who is a current smoker.
Smoking history dictates specific vascular and pulmonary screening requirements.
3
Apply current USPSTF and ACIP guidelines to the patient's profile and past medical history.
At age 65 with a smoking history, he requires abdominal aortic aneurysm screening and ongoing lung cancer screening. As an adult over 50, he requires the zoster vaccine. His prior normal colonoscopy and prior PCV20 dose mean those interventions are not currently due.
To ensure guideline-concordant care without over-testing or over-vaccinating.

Key Concept

Age-appropriate and risk-factor-based preventive screening and immunization in older adults.
Estimated Time:1m 30s
Question 2028Question →

A 56-year-old man presents to the clinic for a follow-up evaluation of gout. He has a history of three acute gouty flares in the past year, affecting his left first metatarsophalangeal joint and right knee. Five weeks ago, he was started on allopurinol 100 mg100\text{ mg} daily for urate-lowering therapy and colchicine 0.6 mg0.6\text{ mg} daily for flare prophylaxis. His medical history is significant for hypertension and stage 3a chronic kidney disease. His estimated glomerular filtration rate is 52 mL/min/1.73 m252\text{ mL/min/1.73 m}^2. Today, he reports feeling well and has not experienced any joint pain since starting the medications.

Laboratory results from today are as follows:

Laboratory ParameterResultReference Range
Serum uric acid7.8 mg/dL7.8\text{ mg/dL}3.5−7.2 mg/dL3.5 - 7.2\text{ mg/dL}
Serum creatinine1.4 mg/dL1.4\text{ mg/dL}0.6−1.2 mg/dL0.6 - 1.2\text{ mg/dL}
Alanine aminotransferase (ALT)22 U/L22\text{ U/L}10−40 U/L10 - 40\text{ U/L}

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Increase the allopurinol dose to 200 mg200\text{ mg} daily and repeat the serum uric acid level in 44 weeks

Answer

Increase the allopurinol dose to 200 mg daily and repeat the serum uric acid level in 4 weeks.
The patient has symptomatic gout and was appropriately started on allopurinol and colchicine. The primary goal of urate-lowering therapy (ULT) is to maintain a serum uric acid level of <6.0 mg/dL< 6.0\text{ mg/dL} (and <5.0 mg/dL< 5.0\text{ mg/dL} in patients with tophaceous gout) to promote the dissolution of monosodium urate crystals. His current level is 7.8 mg/dL7.8\text{ mg/dL}, indicating that the 100 mg100\text{ mg} dose is subtherapeutic. In patients with chronic kidney disease, allopurinol is typically initiated at a low dose (e.g., 50−100 mg50-100\text{ mg} daily) to minimize the risk of allopurinol hypersensitivity syndrome. However, a common clinical misconception is that the dose must be strictly capped based on renal function. Current guidelines emphasize that allopurinol can and should be gradually up-titrated every 2 to 5 weeks until the uric acid target is achieved, regardless of mild to moderate CKD. Therefore, increasing the dose to 200 mg200\text{ mg} daily and rechecking the level in 44 weeks is the most appropriate next step.

Step-by-Step Solution

1
Evaluate the current serum uric acid level against the therapeutic target.
The patient's uric acid is 7.8 mg/dL7.8\text{ mg/dL}, which is above the standard target of <6.0 mg/dL< 6.0\text{ mg/dL}.
Urate-lowering therapy must be titrated to a specific target to ensure the dissolution of monosodium urate crystals.
2
Assess the safety of dose titration in the context of the patient's comorbidities.
Allopurinol can be safely up-titrated in patients with chronic kidney disease.
While initiation doses should be lower in CKD to prevent hypersensitivity, capping the maximum dose prevents patients from reaching therapeutic targets.
3
Determine the appropriate duration for concurrent anti-inflammatory prophylaxis.
Colchicine must be continued for at least 3 to 6 months.
Rapid shifts in serum uric acid during titration can precipitate mobilization flares if prophylaxis is stopped prematurely.
4
Select the correct management step.
Increase the allopurinol dose to 200 mg200\text{ mg} and schedule a re-check in 44 weeks.
This achieves the goal of gradual up-titration with appropriate monitoring intervals.

Key Concept

Allopurinol dose titration to a target serum uric acid of < 6.0 mg/dL
Question 2029Question →

A 71-year-old man presents to the primary care clinic with 2424 hours of severe, sudden-onset pain and swelling in his left big toe. He reports the pain woke him from sleep and is exacerbated by the light touch of his bedsheets. He has a medical history of ischemic cardiomyopathy with a left ventricular ejection fraction of 25%25\%, chronic kidney disease stage 4 with a baseline eGFR of 22 mL/min/1.73 m222 \text{ mL/min/1.73 m}^2, and poorly controlled type 2 diabetes mellitus with a recent HbA1c of 9.2%9.2\%. Three weeks ago, he was hospitalized for an acute heart failure exacerbation, which required increasing his daily furosemide dose. Current medications include lisinopril, carvedilol, furosemide, empagliflozin, and aspirin. Vital signs are within normal limits. Examination reveals an erythematous, exquisitely tender, and swollen left first metatarsophalangeal joint. Arthrocentesis yields synovial fluid with 45,000 leukocytes/\muL45,000 \text{ leukocytes/\mu L} (85%85\% neutrophils). Polarized light microscopy demonstrates negatively birefringent, needle-shaped crystals. Gram stain is negative for organisms. Which of the following is the most appropriate next step in pharmacologic management?

Show answer & explanation

Answer: Intra-articular methylprednisolone injection

Answer

Intra-articular methylprednisolone injection
The correct answer provides localized, targeted anti-inflammatory therapy that avoids the significant systemic toxicities associated with other first-line gout treatments. In a patient with advanced chronic kidney disease, heart failure with recent decompensation, and poorly controlled diabetes, systemic NSAIDs, colchicine, and oral corticosteroids all carry unacceptable risks of precipitating acute renal failure, volume overload, or severe hyperglycemia.

Step-by-Step Solution

1
Analyze the clinical presentation and diagnostic results.
The patient has podagra with negatively birefringent crystals and a negative Gram stain, definitively diagnosing an acute gout flare.
Establishing the correct diagnosis prevents inappropriate interventions like empiric antibiotics.
2
Identify relevant patient comorbidities that impact pharmacologic choices.
The patient has advanced CKD (eGFR < 30), severe HFrEF with recent decompensation, and poorly controlled Type 2 DM.
Treatment selection in acute gout is heavily dependent on patient contraindications.
3
Evaluate the safety of standard first-line therapies (NSAIDs, colchicine, systemic steroids) against the patient's comorbidities.
NSAIDs are contraindicated due to CKD and HFrEF; Colchicine is unsafe due to advanced CKD; Systemic steroids carry high risk due to DM and recent heart failure.
Recognizing overlapping contraindications is critical to avoid iatrogenic harm.
4
Select the optimal targeted therapy.
Intra-articular glucocorticoid injection is chosen.
It successfully treats monoarticular gout while avoiding the systemic adverse effects associated with oral medications.

Key Concept

In patients presenting with acute monoarticular gout who have multiple contraindications to systemic therapies (e.g., advanced CKD, heart failure, poorly controlled diabetes), intra-articular glucocorticoids are the preferred treatment.
Question 2030Question →

A primary care physician is evaluating several patients during a busy morning clinic session. Match each patient's clinical presentation with the most appropriate, guideline-concordant next step in preventive care or screening.

Click a left item, then click its matching right item

Items

A 24-year-old woman at 9 weeks gestation presenting for her initial prenatal visit with no urinary symptoms.
A 52-year-old man with a 10-year history of ulcerative pancolitis currently in clinical remission.
A 66-year-old man with a history of hypertension, a lifelong non-smoker, who has received only influenza vaccines as an adult.
A 42-year-old woman with a BMI of 33 kg/m² who is asymptomatic with normal blood pressure.

Matches

Show answer & explanation

Answer

Match the 24-year-old pregnant woman to the urine culture, the 52-year-old man with ulcerative colitis to the surveillance colonoscopy, the 66-year-old man to the pneumococcal vaccine, and the 42-year-old woman with a BMI of 33 kg/m² to the diabetes screening.
Each correct match directly applies current evidence-based preventive care guidelines established by the USPSTF and ACIP. Pregnant women must be screened for asymptomatic bacteriuria. Long-standing inflammatory bowel disease warrants strict surveillance colonoscopy. Adults over 65 require pneumococcal vaccination. Adults aged 35 to 70 with a BMI of 25 kg/m² or higher require targeted diabetes screening.

Step-by-Step Solution

1
Evaluate the 24-year-old pregnant woman.
Identify the need for routine prenatal screening, specifically for asymptomatic bacteriuria.
Untreated asymptomatic bacteriuria in pregnancy increases the risk of pyelonephritis and preterm delivery.
2
Evaluate the 52-year-old man with prolonged ulcerative pancolitis.
Identify the indication for early and frequent colon cancer surveillance.
Chronic colonic inflammation significantly increases the risk of colorectal cancer, prompting surveillance 8 to 10 years after disease onset.
3
Evaluate the 66-year-old man.
Identify the age-based indication for pneumococcal vaccination.
All adults aged 65 and older are recommended to receive pneumococcal immunization to prevent invasive pneumococcal disease.
4
Evaluate the 42-year-old woman with obesity.
Identify the indication for type 2 diabetes screening based on age and BMI.
Guidelines mandate screening for dysglycemia in overweight or obese adults aged 35 to 70.

Key Concept

Application of age, comorbidity, and condition-specific preventive care guidelines (USPSTF and ACIP).
Estimated Time:1m 30s
Question 2031Question →

An internal medicine physician in an ambulatory clinic is preparing to prescribe oral methotrexate for a patient with newly diagnosed, seropositive rheumatoid arthritis. The patient has no history of liver disease, hematologic abnormalities, or chronic kidney disease. Prior to dispensing the medication and establishing a follow-up schedule, the physician is formulating a comprehensive clinical and laboratory surveillance plan. Which of the following parameters are mandatory to assess at baseline and periodically during ongoing treatment with this pharmacotherapy? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Complete blood count; Hepatic transaminases

Answer

The required parameters to monitor at baseline and periodically for a patient initiating methotrexate are a complete blood count and hepatic transaminases.
Methotrexate is an antimetabolite that competitively inhibits dihydrofolate reductase. Because it disrupts cellular replication, it preferentially affects rapidly dividing cells, making myelosuppression (resulting in leukopenia, thrombocytopenia, or megaloblastic anemia) a primary dose-limiting toxicity. Additionally, methotrexate carries a high risk of cumulative hepatotoxicity, ranging from asymptomatic transaminitis to advanced hepatic fibrosis and cirrhosis. Consequently, clinical guidelines strictly require the assessment of a complete blood count and hepatic transaminases (along with serum creatinine, as the drug is renally cleared) prior to initiation and at regular periodic intervals throughout the duration of therapy.

Step-by-Step Solution

1
Identify the proposed pharmacotherapy and its indication.
The medication is methotrexate, prescribed as a first-line disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis.
Different DMARDs have specific and distinct adverse effect profiles requiring tailored surveillance plans.
2
Recall the mechanism of action and the primary dose-limiting toxicities of the medication.
Methotrexate acts as a folate antimetabolite. Its major adverse effects include myelosuppression, hepatotoxicity, and pulmonary toxicity.
Understanding the toxicity profile dictates the necessary laboratory parameters.
3
Select the guideline-concordant tests required to monitor for these specific toxicities.
A complete blood count is needed to detect leukopenia, anemia, or thrombocytopenia. Hepatic transaminases (AST/ALT) are needed to monitor for drug-induced liver injury.
Guidelines mandate baseline assessment and periodic re-evaluation (e.g., every 2-4 weeks initially, then every 12 weeks) of these parameters to safely maintain therapy.

Key Concept

Methotrexate is an antimetabolite DMARD that carries significant risks of bone marrow suppression and hepatotoxicity, requiring strict baseline and periodic monitoring of a complete blood count and hepatic transaminases.
Question 2032Question →

A 32-year-old female, gravida 3, para 3, is evaluated in the labor and delivery unit for severe vaginal bleeding. She has a history of mild persistent asthma, for which she uses an inhaled corticosteroid and as-needed albuterol. Twenty minutes ago, she delivered a 4.1 kg4.1\text{ kg} (9 lb9\text{ lb}) infant vaginally after a prolonged second stage of labor. The placenta was delivered intact. She now has a continuous, brisk flow of vaginal blood. Her temperature is 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure is 98/60 mm Hg98/60\text{ mm Hg}, and heart rate is 112/min112/\text{min}. The uterus is soft, boggy, and palpated 2 cm2\text{ cm} above the umbilicus. Intravenous oxytocin is running, and bimanual uterine massage is being performed, but the bleeding persists. Estimated blood loss is approximately 1050 mL1050\text{ mL}.

Which of the following pharmacologic agents are appropriate to administer to this patient to control the hemorrhage? (Select 3)

Select all that apply

Show answer & explanation

Answer: Methylergonovine; Misoprostol; Tranexamic acid

Answer

The appropriate medications are Methylergonovine, Misoprostol, and Tranexamic acid.
The correct combination of agents for this patient includes Misoprostol, Methylergonovine, and Tranexamic acid. Postpartum hemorrhage (PPH) most commonly results from uterine atony, which presents as a soft, 'boggy' uterus. Initial management includes fundal massage and intravenous oxytocin. When these fail, secondary uterotonics are required. Misoprostol (a PGE1 analog) is safe and effective across most patient profiles. Methylergonovine (an ergot alkaloid) effectively causes sustained tetanic uterine contractions and is safe here because the patient is normotensive (it is contraindicated in hypertension). Tranexamic acid, an antifibrinolytic, is highly recommended as an early adjunct in PPH management to prevent clot breakdown and reduce mortality.

Step-by-Step Solution

1
Diagnose the cause of bleeding.
The patient has primary postpartum hemorrhage due to uterine atony, evidenced by the boggy uterus and brisk bleeding despite oxytocin and bimanual massage.
Identifying the etiology is required to select appropriate targeted therapies.
2
Review the patient's medical history for contraindications.
The patient has a history of mild persistent asthma. Her blood pressure is normal, indicating no hypertensive disorders of pregnancy.
Secondary uterotonics have specific, absolute contraindications that must be recognized to prevent severe iatrogenic complications.
3
Select appropriate pharmacologic agents.
Methylergonovine, Misoprostol, and Tranexamic acid are selected. Carboprost is specifically excluded due to the patient's asthma.
These selected agents safely promote uterine contraction and clot stabilization without triggering bronchospasm.

Key Concept

In the management of postpartum hemorrhage due to uterine atony, second-line uterotonics must be chosen based on patient comorbidities: carboprost is contraindicated in asthma, and methylergonovine is contraindicated in hypertension.
Estimated Time:1m 30s
Question 2033Question →

A 34-year-old man is evaluated in the outpatient psychiatric clinic for a routine follow-up. He has a history of treatment-resistant schizophrenia and was started on clozapine 6 weeks ago after failing trials of risperidone and olanzapine. His psychiatric symptoms have significantly improved, and he reports no auditory hallucinations for the past two weeks. He currently smokes one pack of cigarettes daily. He feels well and denies fever, chills, sore throat, or fatigue. His vital signs are within normal limits. Baseline laboratory studies prior to initiating clozapine showed a total leukocyte count of 7,200/μL7,200/\mu\text{L} and an absolute neutrophil count (ANC) of 4,500/μL4,500/\mu\text{L}. Today, his total leukocyte count is 3,800/μL3,800/\mu\text{L} and his ANC is 1,300/μL1,300/\mu\text{L}. The patient is not of an ethnicity typically associated with benign ethnic neutropenia. Based on the current monitoring parameters, which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

Show answer & explanation

Answer: Continue clozapine therapy and increase the frequency of absolute neutrophil count monitoring to three times weekly

Answer

The most appropriate next step is to continue the clozapine therapy and increase the frequency of absolute neutrophil count (ANC) monitoring to three times weekly.
The patient has developed mild neutropenia (defined as an ANC between 1,000 and 1,499/μL) while taking clozapine. According to the FDA Clozapine REMS guidelines for patients in the general population (without benign ethnic neutropenia), the appropriate management for mild neutropenia is to continue clozapine treatment but increase the frequency of ANC monitoring to three times weekly. This heightened surveillance must continue until the ANC recovers to the normal range (≥1,500/μL).

Step-by-Step Solution

1
Evaluate the patient's current Absolute Neutrophil Count (ANC) against the established baseline and standard reference ranges.
The current ANC is 1,300/μL, which is a decrease from the baseline of 4,500/μL but remains above 1,000/μL.
Identifying the exact tier of neutropenia is required to apply the Clozapine Risk Evaluation and Mitigation Strategy (REMS) protocol.
2
Categorize the severity of the neutropenia according to Clozapine REMS guidelines for the general population.
An ANC of 1,000 to 1,499/μL is categorized as Mild Neutropenia.
Management pathways strictly depend on whether neutropenia is mild, moderate, or severe.
3
Determine the guideline-directed intervention for mild neutropenia in an asymptomatic patient.
The guidelines mandate continuing clozapine treatment but increasing the frequency of ANC monitoring to three times weekly until the ANC returns to ≥1,500/μL.
This protocol balances the critical need for continued psychiatric stabilization against the risk of progressing to severe agranulocytosis.

Key Concept

Clozapine Risk Evaluation and Mitigation Strategy (REMS) guidelines for monitoring absolute neutrophil count (ANC) and managing treatment-induced neutropenia.
Question 2034Question →

An adult patient is admitted to the cardiac telemetry unit with acute decompensated heart failure, presenting with severe bilateral lower extremity edema, jugular venous distention, and orthopnea. The patient has an established history of heart failure with reduced ejection fraction and routinely takes 40 mg of oral furosemide daily at home. The inpatient medical team plans a structured, stepwise diuretic strategy to safely achieve euvolemia while preserving renal function. Arrange the following steps in the most appropriate chronological sequence for monitoring diuretic response and sequentially adapting treatment in this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is to first administer an initial IV loop diuretic, then evaluate urine sodium and output at 2 hours, double the IV loop diuretic dose if the initial response is inadequate, initiate sequential nephron blockade with a thiazide if maximum doses fail, and finally transition to an oral maintenance regimen once euvolemic.
The correct sequence mirrors the standardized guideline-directed algorithm for diuretic resistance in acute decompensated heart failure. It begins with establishing adequate initial IV dosing to bypass impaired gut absorption. Rather than waiting 24 hours, the response must be evaluated early (at 2 hours) via urine sodium or volume to adapt the treatment dynamically. If the threshold for diuresis is not met, the loop diuretic dose must be doubled to achieve an effective peak concentration. Only if the patient remains unresponsive at maximal loop diuretic doses should a thiazide-like diuretic be added to block compensatory distal sodium reabsorption. The final step is transitioning to oral therapy once euvolemia allows for reliable gut absorption.

Step-by-Step Solution

1
Administer an initial IV bolus of a loop diuretic.
Delivers the diuretic directly to the systemic circulation.
Gut wall edema in acute decompensated heart failure significantly impairs the absorption of oral diuretics. IV administration bypasses this barrier.
2
Evaluate spot urine sodium and total urine output at the 2-hour mark.
Identifies early diuretic resistance.
Waiting 24 hours to assess daily output delays necessary care. The 2-hour assessment allows for rapid treatment adaptation and step-up therapy.
3
Double the IV loop diuretic dose if 2-hour targets are not achieved.
Increases the peak concentration of the diuretic.
Loop diuretics have a threshold effect. If the initial dose does not reach the necessary concentration in the tubular lumen, frequency adjustments will fail; the dose must be doubled.
4
Add a thiazide-like diuretic for persistent resistance.
Induces sequential nephron blockade.
Chronic loop diuretic use causes distal tubule hypertrophy. Adding a distally acting agent prevents the reabsorption of sodium that escapes the loop of Henle.
5
Transition to an oral maintenance regimen.
Prepares the patient for safe hospital discharge.
Once euvolemia is reached, gut absorption normalizes, allowing for a successful and stable switch back to oral pharmacotherapy.

Key Concept

Sequential step-up pharmacological therapy and rapid monitoring (e.g., 2-hour spot urine sodium) in acute decompensated heart failure.
Question 2035Question →

A 6868-year-old woman is evaluated in the emergency department for a 22-day history of fever, chills, right-sided flank pain, and nausea. Her medical history is significant for a mechanical mitral valve replacement 44 years ago, paroxysmal atrial fibrillation, and recurrent urinary tract infections. Her medications include warfarin and metoprolol. Two months ago, she was hospitalized for pyelonephritis, and blood and urine cultures at that time grew Klebsiella pneumoniae confirmed to be an extended-spectrum beta-lactamase (ESBL) producer.

Upon arrival, her temperature is 39.2∘C39.2^{\circ}\text{C} (102.6∘F102.6^{\circ}\text{F}), blood pressure is 88/54 mmHg88/54\text{ mmHg}, pulse is 118/min118/\text{min} and irregularly irregular, and respiratory rate is 22/min22/\text{min}. Physical examination reveals marked right costovertebral angle tenderness.

Laboratory results:
Leukocyte count: 18,500/mm318,500/\text{mm}^3
Serum creatinine: 2.4 mg/dL2.4\text{ mg/dL} (baseline 0.8 mg/dL0.8\text{ mg/dL})
INR: 3.23.2
Urinalysis: 3+3+ leukocyte esterase, positive nitrites, >50 WBCs/hpf>50\text{ WBCs/hpf}

The patient receives a 30 mL/kg30\text{ mL/kg} intravenous bolus of lactated Ringer solution. Repeat blood pressure is 112/68 mmHg112/68\text{ mmHg}. Blood and urine cultures are obtained. Which of the following is the most appropriate next pharmacologic intervention?

Show answer & explanation

Answer: Intravenous meropenem

Answer

Intravenous meropenem
The correct pharmacologic intervention is intravenous meropenem. This patient presents with sepsis secondary to acute pyelonephritis and acute kidney injury. Her recent history of infection with an extended-spectrum beta-lactamase (ESBL)-producing organism places her at high risk for a recurrent ESBL infection. Carbapenems, such as meropenem, ertapenem, and imipenem, are the standard-of-care empiric therapy for severe, life-threatening infections caused by ESBL-producing Enterobacteriaceae. Since she has already responded appropriately to initial fluid resuscitation, the immediate administration of a guideline-concordant intravenous antibiotic is the critical next step.

Step-by-Step Solution

1
Diagnose the acute clinical presentation.
The patient has urosepsis secondary to acute pyelonephritis, complicated by acute kidney injury (AKI).
Fever, CVA tenderness, hypotension, leukocytosis, and pyuria confirm the diagnosis and the need for immediate, broad-spectrum intravenous antibiotics following fluid resuscitation.
2
Analyze microbiological risk factors.
The patient has a known history of infection with ESBL-producing Klebsiella pneumoniae.
Prior colonization or infection with ESBL organisms is the strongest predictor for recurrent ESBL infection, mandating empiric coverage with a carbapenem (e.g., meropenem, ertapenem).
3
Evaluate comorbid conditions and current medications against therapeutic options.
The patient has a mechanical mitral valve with a therapeutic INR (3.23.2), and acute kidney injury.
This rules out interventions that would cause dangerous drug-drug interactions (e.g., fluoroquinolones potentiating warfarin), interventions contraindicated by renal failure (e.g., nitrofurantoin), and unnecessary reversal of anticoagulation.

Key Concept

Empiric antibiotic selection for urosepsis must account for past resistant isolates (e.g., utilizing carbapenems for known ESBL history) while strictly avoiding agents contraindicated by the patient's comorbidities (AKI) or current pharmacotherapy (warfarin).
Estimated Time:1m 30s
Question 2036Question →

A 43-year-old male arrives at the internal medicine clinic for a routine wellness evaluation. He has no acute symptoms and generally feels well. His past medical history is notable only for mild hyperlipidemia, for which he takes rosuvastatin and follows a heart-healthy diet. He exercises regularly, drinks alcohol on social occasions, and has never smoked or used illicit substances. His family history is significant for a father who was diagnosed with colon cancer at age 51. The patient has never undergone any gastrointestinal endoscopic procedures or noninvasive colorectal cancer screening. His vital signs are within normal limits, and his physical examination is unremarkable. Which of the following is the most appropriate next step regarding colorectal cancer screening for this patient?

Show answer & explanation

Answer: Perform a screening colonoscopy now

Answer

Perform a screening colonoscopy now
The correct action is to perform a screening colonoscopy now. According to current preventive guidelines, patients with a single first-degree relative diagnosed with colorectal cancer or an advanced adenoma before the age of 60 are considered at high risk. For these high-risk individuals, screening must be performed exclusively via colonoscopy. The recommended starting age is 40 years, or 10 years earlier than the youngest affected relative's age at diagnosis, whichever comes first. In this vignette, the patient's father was diagnosed at age 51. Ten years prior to the father's diagnosis is age 41. Because age 40 is earlier than 41, the patient should have begun screening at age 40. At 43 years of age with no prior screening history, he is overdue and requires an immediate screening colonoscopy.

Step-by-Step Solution

1
Assess the patient's risk category based on his family history.
The patient has a first-degree relative (father) diagnosed with colon cancer at age 51, placing him in a high-risk category.
Family history dictates the modality, starting age, and frequency of colorectal cancer screening.
2
Determine the recommended screening modality for high-risk patients.
High-risk patients must be screened using direct visualization via colonoscopy, rather than stool-based noninvasive tests.
Colonoscopy provides the highest sensitivity and allows for immediate therapeutic intervention (polypectomy) in populations with elevated pretest probability.
3
Calculate the correct starting age for this patient's screening.
Guidelines recommend starting at age 40, or 10 years prior to the relative's diagnosis (age 41). The earlier of these two is age 40.
The 10-year rule accounts for the estimated time it takes for an adenoma to transform into a carcinoma.
4
Compare the calculated starting age with the patient's current age.
The patient is 43 years old and has never been screened, meaning he is overdue for a colonoscopy.
Immediate scheduling of a colonoscopy is the necessary guideline-concordant next step.

Key Concept

High-risk colorectal cancer screening guidelines based on family history
Estimated Time:1m 0s
Question 2037Question →

A 19-year-old male is evaluated in the dermatology clinic for severe, scarring nodulocystic acne on his face, chest, and back. He has not experienced meaningful improvement despite a 4-month trial of oral doxycycline and topical tretinoin. The physician decides to initiate therapy with oral isotretinoin. The patient has no other medical history and takes no other medications. Which of the following evaluations are essential to perform prior to initiating and periodically during this specific pharmacotherapy? (Select 2)

Select all that apply

Show answer & explanation

Answer: Fasting lipid panel; Hepatic function panel

Answer

The essential baseline and ongoing evaluations for this patient are a fasting lipid panel and a hepatic function panel.
Oral isotretinoin is a highly effective treatment for severe nodular acne, but it carries a risk of significant adverse effects. The most common laboratory abnormalities associated with isotretinoin therapy are hypertriglyceridemia, hypercholesterolemia, and elevated liver transaminases. Therefore, baseline and periodic monitoring of a fasting lipid panel and hepatic function panel (AST, ALT, bilirubin) are universally required to prevent complications such as acute pancreatitis or hepatotoxicity. For female patients of childbearing potential, strict pregnancy testing is also mandatory due to severe teratogenicity, but this is not applicable to this male patient.

Step-by-Step Solution

1
Identify the high-risk pharmacotherapy indicated by the clinical vignette.
The patient is starting oral isotretinoin for severe, refractory nodulocystic acne.
Recognizing the specific medication is required to determine the appropriate monitoring protocol.
2
Determine the primary physiological adverse effects associated with the selected medication.
Oral isotretinoin frequently causes hypertriglyceridemia and elevated liver transaminases.
Understanding the drug's toxicity profile allows the clinician to select targeted, highly specific surveillance parameters.
3
Select the corresponding diagnostic evaluations for the identified physiological risks.
A fasting lipid panel and a hepatic function panel are chosen to monitor for these metabolic and hepatic derangements.
These tests detect asymptomatic adverse effects before severe complications, such as acute pancreatitis or overt hepatotoxicity, can occur.

Key Concept

Monitoring parameters for oral isotretinoin therapy
Question 2038Question →

A 32-year-old woman is admitted to the hospital with acute-onset right leg pain and swelling. Venous duplex ultrasonography reveals a deep vein thrombosis in the right femoral and popliteal veins. Her medical history is significant for systemic lupus erythematosus and antiphospholipid syndrome. She previously experienced a deep vein thrombosis three years ago and was treated with warfarin, but she discontinued all medications one year ago. Her vital signs are stable, and physical examination is notable only for right lower extremity pitting edema and erythema. She has no active bleeding.

Baseline laboratory studies obtained prior to treatment show:

Laboratory TestResultReference Range
Hemoglobin12.1 g/dL12.0-16.0 g/dL
Platelet count190,000/mm³150,000-400,000/mm³
Creatinine0.9 mg/dL0.6-1.1 mg/dL
Prothrombin time (PT)12.5 seconds11.0-15.0 seconds
Activated partial thromboplastin time (aPTT)82 seconds25-40 seconds

The physician orders a continuous intravenous infusion of unfractionated heparin for acute anticoagulation. Six hours after the initiation of the heparin infusion, a repeat aPTT is reported as >150 seconds. The patient continues to have no signs of bleeding.

Which of the following is the best next step in monitoring and evaluating this patient's anticoagulant therapy?

Show answer & explanation

Answer: Measure unfractionated heparin levels using an anti-factor Xa assay

Answer

Measure unfractionated heparin levels using an anti-factor Xa assay.
The correct answer is to measure unfractionated heparin levels using an anti-factor Xa assay. This patient has a known history of antiphospholipid syndrome, which frequently involves the presence of a circulating lupus anticoagulant. Lupus anticoagulants are autoantibodies that bind to phospholipids. Because the activated partial thromboplastin time (aPTT) assay relies on phospholipids to trigger coagulation in vitro, the presence of these antibodies causes a baseline prolongation of the aPTT. This is a purely in vitro phenomenon; in vivo, these patients are highly prothrombotic. When a patient with a prolonged baseline aPTT requires continuous unfractionated heparin therapy for an acute thrombosis, the aPTT becomes completely unreliable for monitoring the degree of anticoagulation. Attempting to use a standard aPTT nomogram in this setting often leads to dangerous underdosing of heparin and extension of the thrombus. Instead, clinicians must use the anti-factor Xa assay. This assay measures the specific ability of the patient's heparin-antithrombin complex to inhibit factor Xa; it does not utilize phospholipid reagents and is therefore not affected by the lupus anticoagulant.

Step-by-Step Solution

1
Analyze the patient's baseline laboratory values in the context of her medical history.
The baseline aPTT is significantly prolonged (82 seconds) prior to the administration of any anticoagulant, which is consistent with her history of systemic lupus erythematosus and antiphospholipid syndrome.
Antiphospholipid antibodies (specifically lupus anticoagulant) bind to the phospholipids used in the aPTT assay, causing an in vitro prolongation of the clotting time despite promoting a prothrombotic state in vivo.
2
Evaluate the standard monitoring protocol for the prescribed therapy.
Unfractionated heparin infusions are typically monitored using the aPTT, with dose adjustments made to achieve a target range (usually 1.5 to 2.5 times the normal baseline).
Heparin binds to antithrombin, enhancing its inhibition of thrombin and factor Xa, which is reflected in a prolonged aPTT.
3
Determine if the standard monitoring parameter is valid for this specific patient.
The aPTT is invalid for monitoring heparin in this patient.
Because the baseline aPTT is already artifactually prolonged by the lupus anticoagulant, the standard aPTT nomograms cannot accurately reflect the true degree of in vivo anticoagulation achieved by the heparin infusion.
4
Identify the most appropriate alternative monitoring test.
The anti-factor Xa assay should be ordered.
The anti-factor Xa assay directly measures the ability of heparin-bound antithrombin to inhibit factor Xa. It does not rely on phospholipid reagents and is therefore unaffected by the presence of a lupus anticoagulant.

Key Concept

In patients with antiphospholipid syndrome who have a prolonged baseline aPTT due to a lupus anticoagulant, the anti-factor Xa assay must be used instead of the aPTT to accurately monitor unfractionated heparin infusions.
Question 2039Question →

A 53-year-old man is brought to the emergency department after falling from a 20-foot scaffolding. He is unresponsive and has a Glasgow Coma Scale score of 6 (Eye 1, Verbal 1, Motor 4). His pupils are equal and reactive, but he has a large right frontal hematoma. Vital signs are temperature 36.5°C (97.7°F), heart rate 108/min, blood pressure 172/98 mmHg, and respiratory rate 22/min. The trauma team decides to secure the airway via rapid sequence intubation (RSI) using a neuroprotective strategy to mitigate potential spikes in intracranial pressure. Pre-oxygenation with 100% oxygen is initiated.

Arrange the following pharmacologic agents in the correct chronological sequence of administration according to standard rapid sequence intubation protocols for this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence of administration is Fentanyl, followed by Etomidate, followed by Rocuronium, and finally a Propofol continuous infusion.
Standard rapid sequence intubation involves sequential phases: preparation, preoxygenation, pretreatment, paralysis with induction, positioning, placement, and post-intubation management. Pretreatment (such as fentanyl) mitigates the physiologic response to laryngoscopy and should be given first. Induction (etomidate) rapidly produces unconsciousness. Paralysis (rocuronium) must immediately follow induction to facilitate tube placement. Finally, post-intubation management requires starting a continuous sedative infusion (propofol) to ensure the patient does not awaken while still paralyzed by the long-acting neuromuscular blocker.

Step-by-Step Solution

1
Administer pretreatment
Sympathetic blunting achieved
Intravenous fentanyl is given approximately 3 minutes before induction to prevent surges in intracranial pressure and blood pressure associated with airway manipulation.
2
Administer induction agent
Rapid unconsciousness induced
Intravenous etomidate is given as the induction agent to render the patient unconscious while maintaining hemodynamic stability.
3
Administer neuromuscular blockade
Complete chemical paralysis achieved
Intravenous rocuronium is pushed immediately after the patient loses consciousness to paralyze the vocal cords and skeletal muscles, facilitating endotracheal intubation.
4
Initiate post-intubation sedation
Ongoing sedation maintained
Once the endotracheal tube is confirmed, a continuous intravenous propofol infusion is started to keep the paralyzed patient adequately sedated.

Key Concept

Rapid Sequence Intubation (RSI) Pharmacologic Sequencing
Estimated Time:1m 0s
Question 2040Question →

A male patient in his late seventies is evaluated in the emergency department for profound weakness, lightheadedness, and multiple episodes of large-volume melena that began 12 hours ago. Four days prior, he was evaluated at an urgent care clinic for a mild exacerbation of chronic obstructive pulmonary disease characterized by increased dyspnea and purulent sputum. At that time, his chronic medications—apixaban, lisinopril, tiotropium, and formoterol—were continued without dosage adjustments. He was additionally prescribed a five-day course of oral prednisone and an empiric oral antimicrobial. On presentation to the emergency department, his blood pressure is 88/54 mmHg and his pulse is 115/min. Laboratory studies reveal a hemoglobin concentration of 7.6 g/dL (down from a baseline of 13.8 g/dL three months ago) and a serum creatinine of 1.2 mg/dL. Which of the following antimicrobials was most likely prescribed during the urgent care visit?

Show answer & explanation

Answer: Clarithromycin

Answer

The correct answer is clarithromycin.
Clarithromycin is a strong dual inhibitor of both the cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) efflux transporter. Apixaban is a direct factor Xa inhibitor that heavily relies on both CYP3A4 for hepatic metabolism and P-gp for biliary and intestinal excretion. When clarithromycin is co-administered with apixaban, the clearance of apixaban is markedly reduced, leading to a profound, rapid increase in plasma drug concentrations. This pharmacokinetic interaction significantly amplifies the systemic anticoagulant effect, directly resulting in the patient's acute, massive gastrointestinal hemorrhage. In standard clinical practice, strong dual CYP3A4 and P-gp inhibitors must be avoided in patients taking full-dose apixaban, or the apixaban dose must be empirically halved.

Step-by-Step Solution

1
Identify the primary clinical problem and its timeline.
The patient presents with an acute, life-threatening gastrointestinal hemorrhage (melena, shock, hemoglobin drop) four days after adding new medications to a stable regimen.
Establishing the timeline points to an acute drug-drug interaction or adverse drug event as the precipitating cause.
2
Analyze the patient's baseline medications for bleeding risk.
The patient is taking apixaban, a direct oral anticoagulant (DOAC), which inherently carries a risk of bleeding.
DOACs have specific metabolic pathways; recognizing these pathways is necessary to identify potential drug interactions.
3
Determine the metabolic clearance mechanisms for the baseline anticoagulant.
Apixaban is cleared through hepatic metabolism primarily by the cytochrome P450 3A4 (CYP3A4) enzyme and is pumped out of cells into the gut lumen and bile by the P-glycoprotein (P-gp) efflux transporter.
Understanding the pharmacokinetics of apixaban isolates which types of newly added drugs will cause toxicity.
4
Evaluate the added antimicrobials for their ability to alter apixaban clearance.
Among the common medications for a COPD exacerbation, clarithromycin is a potent dual inhibitor of both CYP3A4 and P-gp.
Inhibition of these pathways leads to a massive accumulation of apixaban in the blood, culminating in severe, acute bleeding.

Key Concept

Pharmacokinetic drug interactions with direct oral anticoagulants (DOACs)
PreviousPage 102 / 104Next
Patient Management Practice Questions — USMLE Step 3 — Page 102 | Examkin